Trimetazidine Blocks Lipid Oxidation-Should it be Repurposed for Prevention and Treatment of Diabetic Ketoacidosis?
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
Journal of diabetes science and technology - 16(2022), 5 vom: 12. Sept., Seite 1063-1068 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Klonoff, David C [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Blood Glucose |
|---|
| Anmerkungen: |
Date Completed 08.09.2022 Date Revised 14.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1177/19322968221100196 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM34174607X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM34174607X | ||
| 003 | DE-627 | ||
| 005 | 20240214232525.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1177/19322968221100196 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1292.xml |
| 035 | |a (DE-627)NLM34174607X | ||
| 035 | |a (NLM)35652624 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Klonoff, David C |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Trimetazidine Blocks Lipid Oxidation-Should it be Repurposed for Prevention and Treatment of Diabetic Ketoacidosis? |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.09.2022 | ||
| 500 | |a Date Revised 14.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Editorial | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a SGLT2 inhibitor | |
| 650 | 4 | |a ketoacidosis | |
| 650 | 4 | |a metabolic modulator | |
| 650 | 4 | |a repurpose | |
| 650 | 4 | |a trimetazidine | |
| 650 | 7 | |a Blood Glucose |2 NLM | |
| 650 | 7 | |a Lipids |2 NLM | |
| 650 | 7 | |a Trimetazidine |2 NLM | |
| 650 | 7 | |a N9A0A0R9S8 |2 NLM | |
| 700 | 1 | |a Xu, Nicole Y |e verfasserin |4 aut | |
| 700 | 1 | |a Nguyen, Kevin T |e verfasserin |4 aut | |
| 700 | 1 | |a Kerr, David |e verfasserin |4 aut | |
| 700 | 1 | |a Mehta, Chhavi |e verfasserin |4 aut | |
| 700 | 1 | |a Umpierrez, Guillermo E |e verfasserin |4 aut | |
| 700 | 1 | |a Brooks, George A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of diabetes science and technology |d 2007 |g 16(2022), 5 vom: 12. Sept., Seite 1063-1068 |w (DE-627)NLM179163914 |x 1932-2968 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2022 |g number:5 |g day:12 |g month:09 |g pages:1063-1068 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1177/19322968221100196 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2022 |e 5 |b 12 |c 09 |h 1063-1068 | ||